Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
NEW YORK, April 30, 2018 -- Maxim Group LLC, a leading full service investment banking, securities and wealth management firm today announced the expansion of its Equity Research platform with the appointment of Caroline Palomeque as a Senior Vice President and Senior Biotechnology Analyst.
Prior to joining Maxim Group, Ms. Palomeque was a Senior Research Analyst covering the Biotechnology sector at Noble Life Science Partners and WallachBeth Capital. She has equity research experience at Oppenheimer, JMP Securities, Goldman Sachs, and Natexis Bleichroeder. Ms. Palomeque has conducted research at Mount Sinai School of Medicine in molecular epidemiology and neurotoxins. She also coauthored several scientific papers which were peer-reviewed academic journals. “I am pleased to add someone with Caroline’s experience background to our Healthcare Platform. Healthcare is a core vertical at Maxim Group and Biotechnology is an important component,” said Anthony V. Vendetti, Executive Managing Director and Head of Equity Research at Maxim Group.
Ms. Palomeque holds an M.B.A. in Finance from Fordham University Graduate School of Business and a B.S. in Neuroscience from the University of Massachusetts Amherst.
About Maxim Group LLC
Maxim Group LLC is a full-service investment banking, securities and wealth management firm headquartered in New York. The Firm provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed-income and derivatives sales & trading, equity research and prime brokerage services to a diverse range of corporate clients, institutional investors and high net worth individuals. Maxim Group is a registered broker-dealer with the U.S. Securities and Exchange Commission (SEC) and the Municipal Securities Rulemaking Board (MSRB), and is a member of the following: Financial Industry Regulatory Authority (FINRA); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and NYSE Arca, Inc. To learn more about Maxim Group, visit www.maximgrp.com.
For further information please contact:
John J. Garrity
Chief Marketing Officer
212.895.3624
[email protected]
